symbol,statement_type,period_end,line_item,value
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.256719
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Normalized EBITDA,10701600000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,6595800000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,1710400000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,13165500000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,EBITDA,10701600000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,EBIT,8991200000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Net Interest Income,-117300000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Interest Expense,117300000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Interest Income,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Normalized Income,6595800000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,6595800000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Total Expenses,30571900000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Diluted Average Shares,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Basic Average Shares,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Diluted EPS,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Basic EPS,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,6595800000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,6595800000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Net Income,6595800000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Minority Interests,0.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,6595800000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,6595800000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Tax Provision,2278100000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Pretax Income,8873900000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,383200000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Special Income Charges,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Other Special Charges,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Write Off,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-117300000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,117300000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Operating Income,8608000000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Operating Expense,17406400000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Other Operating Expenses,8819900000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,1710400000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,1710400000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Selling General And Administration,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Gross Profit,26014400000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Cost Of Revenue,13165500000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Total Revenue,39179900000.0
JBCHEPHARM.NS,income,2025-03-31 00:00:00,Operating Revenue,39179900000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.264641
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Normalized EBITDA,9341600000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items,328652000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,328652000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,5526300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,1383200000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,11820500000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,EBITDA,9341600000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,EBIT,7958400000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Net Interest Income,-443300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Interest Expense,443300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Interest Income,44277000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Normalized Income,5526300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,5526300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Total Expenses,27256100000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,20169000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Diluted Average Shares,158573888.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Basic Average Shares,154971957.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Diluted EPS,34.85
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Basic EPS,35.66
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,5526300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,5526300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Net Income,5526300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Minority Interests,0.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,5526300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,5526300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Tax Provision,1988800000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Pretax Income,7515100000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,372700000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Special Income Charges,1225000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Other Special Charges,-1225000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Write Off,
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-443300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,6762000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,443300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,44277000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Operating Income,7585700000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Operating Expense,15435600000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Other Operating Expenses,8038300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,1383200000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,1383200000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Selling General And Administration,4155098000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,3818072000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,General And Administrative Expense,337026000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,20169000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Gross Profit,23021300000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Cost Of Revenue,11820500000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Total Revenue,34841800000.0
JBCHEPHARM.NS,income,2024-03-31 00:00:00,Operating Revenue,34841800000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,19810906.148702
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.261561
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Normalized EBITDA,6974738000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items,75741000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,75741000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,4098355000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,1144069000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,11847974000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,EBITDA,7050479000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,EBIT,5906410000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Net Interest Income,-335169000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Interest Expense,354084000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Interest Income,25362000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Normalized Income,4042424906.148702
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,4098355000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Total Expenses,25290168000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,29508000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Diluted Average Shares,78308798.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Basic Average Shares,77324995.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Diluted EPS,26.17
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Basic EPS,26.5
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,4098355000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,4098355000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Net Income,4098355000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Minority Interests,-1698000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,4100053000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,4100053000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Tax Provision,1452273000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Pretax Income,5552326000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,3658000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Special Income Charges,6743000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Other Special Charges,-6743000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Write Off,
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-335169000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,6447000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,354084000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,25362000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Operating Income,5874888000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Operating Expense,13442194000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Other Operating Expenses,3038827000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,1144069000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,1144069000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Selling General And Administration,3752897000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,3384979000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,General And Administrative Expense,367918000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,29508000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Gross Profit,19317082000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Cost Of Revenue,11847974000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Total Revenue,31165056000.0
JBCHEPHARM.NS,income,2023-03-31 00:00:00,Operating Revenue,31165056000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.235413
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Normalized EBITDA,5826800000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items,374479000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,374479000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,3853600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,726600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,8429400000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,EBITDA,5826800000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,EBIT,5100200000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Net Interest Income,-51200000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Interest Expense,51200000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Interest Income,9343000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Normalized Income,3853600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,3853600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Total Expenses,19534500000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,13403000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Diluted Average Shares,154700923.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Basic Average Shares,154576815.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Diluted EPS,24.91
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Basic EPS,24.93
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,3853600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,3853600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Net Income,3853600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Minority Interests,-6800000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,3860400000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,3860400000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Tax Provision,1188600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Pretax Income,5049000000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,392300000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Special Income Charges,24049000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Other Special Charges,-24049000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Write Off,
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-51200000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,3352000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,51200000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,9343000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Operating Income,4707900000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Operating Expense,11105100000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Other Operating Expenses,5986100000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,726600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,726600000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Selling General And Administration,3160995000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,2581088000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,General And Administrative Expense,579907000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,13403000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Gross Profit,15813000000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Cost Of Revenue,8429400000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Total Revenue,24242400000.0
JBCHEPHARM.NS,income,2022-03-31 00:00:00,Operating Revenue,24242400000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items,1029102000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,1029102000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,EBITDA,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,EBIT,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Net Interest Income,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Interest Expense,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Interest Income,17740000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Normalized Income,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Total Expenses,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,11486000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Diluted Average Shares,154564194.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Basic Average Shares,154564194.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Diluted EPS,28.98
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Basic EPS,28.98
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Net Income,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Minority Interests,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Tax Provision,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Pretax Income,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Special Income Charges,523599000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Other Special Charges,-524367000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Write Off,768000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,2983000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,17740000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Operating Income,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Operating Expense,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Selling General And Administration,1980462000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,1770870000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,General And Administrative Expense,209592000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,11486000.0
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Gross Profit,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Total Revenue,
JBCHEPHARM.NS,income,2021-03-31 00:00:00,Operating Revenue,
